Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.01B
- P/E ratio
- —
- EPS
- —
- Volume
- 608,294
- 52-week high
- —
- 52-week low
- —
- Open
- $10.90
- Day high
- $11.22
- Day low
- $10.59
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $175.11M | -$221.25M | -$3.03 |
| 2024 | $55.25M | -$334.33M | -$5.29 |
| 2023 | $682K | -$201.59M | -$3.93 |
| 2022 | $0 | -$197.72M | -$5.05 |
| 2021 | — | -$143.88M | -$3.89 |
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
- CEO
- Steven L. Basta
- Employees
- 427
- Country
- US
- IPO date
- Oct 25, 2019
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Phathom Pharmaceuticals, Inc.'s stock price today?
- PHAT is trading at $10.65 as of Jul 20, 2026.
- What is Phathom Pharmaceuticals, Inc.'s market cap?
- Phathom Pharmaceuticals, Inc. (PHAT) has a market capitalization of $1.01B.
- Does Phathom Pharmaceuticals, Inc. pay a dividend?
- Phathom Pharmaceuticals, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Phathom Pharmaceuticals, Inc. in?
- Phathom Pharmaceuticals, Inc. operates in the Healthcare sector.